Galectin Therapeutic (GALT) 2.47 $GALT
Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
GlobeNewswire - Wed Aug 31, 7:00AM CDT
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the Company's president, chief executive officer and chief medical officer, will present at Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 3:50 p.m. Eastern time. The conference is being held at the New York Palace Hotel in New York City on September 11-13, 2016.
GALT: 2.47 (+0.55)
Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial
GlobeNewswire - Thu Aug 25, 7:00AM CDT
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announces interim results from an exploratory, open-label, Phase 2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis.
GALT: 2.47 (+0.55)
Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Tue Aug 09, 7:00AM CDT
Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September
GALT: 2.47 (+0.55)
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis
GlobeNewswire - Tue Aug 02, 7:45AM CDT
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the completion of patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis (the NASH-CX trial). The Company expects to report the topline results of this trial in December 2017, as previously planned.
GALT: 2.47 (+0.55)
Galectin Therapeutics (GALT) Jumps: Stock Rises 17.1%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:25AM CDT
Galectin Therapeutics, Inc. (GALT) moved big last session, as its shares jumped a little over 17% on the day.
GALT: 2.47 (+0.55)
Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension
GlobeNewswire - Thu Jun 02, 7:00AM CDT
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that GR-MD-02, its development-stage galectin-3 (gal-3) inhibitor, has shown a positive effect on vascular remodeling in an animal model of pulmonary arterial hypertension (PAH). The results were presented at the American Thoracic Society (ATS) 2016 International Conference by investigators from the Vascular Biology Center and the Department of Pharmacology and Toxicology at Augusta University (formerly known as Georgia Regents University) (see poster presentation).
GALT: 2.47 (+0.55)
Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis
GlobeNewswire - Mon May 16, 3:05PM CDT
A significant clearing of psoriasis in first four patients prompts the extension of treatment for an additional 12 weeks
GALT: 2.47 (+0.55)
Galectin Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Tue May 10, 7:00AM CDT
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three months ended March 31, 2016. These results are included in the Company's Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov.
GALT: 2.47 (+0.55)
Preclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at the American Thoracic Society 2016 International Conference
GlobeNewswire - Thu May 05, 7:01AM CDT
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, has received notification that its collaborative abstract with investigators at Augusta University "Galectin-3 Mediates Vascular Remodeling in Pulmonary Arterial Hypertension" has been accepted for presentation at the American Thoracic Society (ATS) 2016 International Conference, taking place May 13-18 in San Francisco.
GALT: 2.47 (+0.55)
Global Moderate Psoriasis Therapeutics Development Pipeline Review, H2 2015
M2 - Wed Feb 03, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/svzcsv/moderate) has announced the addition of the "Moderate Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Moderate Psoriasis Overview - Therapeutics Development - Pipeline Products for Moderate Psoriasis - Overview - Pipeline Products for Moderate Psoriasis - Comparative Analysis - Moderate Psoriasis - Therapeutics under Development by Companies - Moderate Psoriasis - Therapeutics under Investigation by Universities/Institutes - Moderate Psoriasis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Moderate Psoriasis - Products under Development by Companies - Moderate Psoriasis - Products under Investigation by Universities/Institutes - Moderate Psoriasis - Companies Involved in Therapeutics Development - AbGenomics International, Inc. - ADC Therapeutics Sarl - Almirall, S.A. - AstraZeneca Plc - Avexxin AS - Boehringer Ingelheim GmbH - Celgene Corporation - Convoy Therapeutics, Inc. - Crescendo Biologics Limited - Delenex Therapeutics AG - Eli Lilly and Company - Forward Pharma A/S - Galectin Therapeutics, Inc. - GlycoMar Limited - Idera Pharmaceuticals, Inc. - Johnson & Johnson - Merck KGaA - OPKO Health, Inc. - Sandoz International GmbH - Soligenix, Inc. - Sun Pharma Advanced Research Company Ltd. - Syntrix Biosystems, Inc. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/svzcsv/moderate
JNJ: 118.28 (+0.33), IDRA: 2.66 (-0.18), OPK: 10.56 (+0.06), FWP: 21.00 (-0.60), AZN: 33.58 (-0.07), GALT: 2.47 (+0.55), LLY: 80.44 (+0.56), VRX.TO: 35.38 (+0.55), CELGZ: 1.25 (+0.05)
Galectin Therapeutics to Present at Upcoming Conferences
GlobeNewswire - Thu Jan 28, 7:00AM CST
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today Peter G. Traber, MD, the Company's president, chief executive officer and chief medical officer will present at the 18 Annual BIO CEO & Investor Conference on February 8, 2016, at 10:30 a.m. and at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on February 11, 2016, at 12:00 p.m. Eastern Standard Time.
GALT: 2.47 (+0.55)
Myocardial Fibrosis Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/nbcrfp/myocardial) has announced the addition of the "Myocardial Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Myocardial Fibrosis Overview - Therapeutics Development - Pipeline Products for Myocardial Fibrosis - Overview - Pipeline Products for Myocardial Fibrosis - Comparative Analysis - Myocardial Fibrosis - Therapeutics under Development by Companies - Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes - Myocardial Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myocardial Fibrosis - Products under Development by Companies - Myocardial Fibrosis - Products under Investigation by Universities/Institutes - Myocardial Fibrosis - Companies Involved in Therapeutics Development - AstraZeneca Plc - BioLineRx, Ltd. - Digna Biotech, S.L. - Evotec AG - Galectin Therapeutics, Inc. - GTx, Inc. - MandalMed, Inc. - miRagen Therapeutics, Inc. - ProMetic Life Sciences Inc. - Virocan Therapeutics Private Limited For more information visit http://www.researchandmarkets.com/research/nbcrfp/myocardial
GTXI: 0.74 (-0.02), AZN: 33.58 (-0.07), GALT: 2.47 (+0.55)
Galectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors
GlobeNewswire - Fri Jan 08, 7:10AM CST
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the election of Marc Rubin, M.D. as Chairman of the Board of Directors. Dr. Rubin, who has been serving as lead independent Director, succeeds James C. Czirr, who helped found the Company in 2000 and has served as Executive Chairman for the past seven years. Mr. Czirr will continue to serve as a Director. Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and Board experience in the development and commercialization of pharmaceuticals.
CRIS: 2.33 (-0.04), TTNP: 6.05 (-0.02), GALT: 2.47 (+0.55)
Pulmonary Fibrosis - Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/76pwpp/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Pulmonary Fibrosis - Overview - Pipeline Products for Pulmonary Fibrosis - Comparative Analysis - Pulmonary Fibrosis - Therapeutics under Development by Companies - Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Pulmonary Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pulmonary Fibrosis - Products under Development by Companies - Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Angion Biomedica Corp. - aTyr Pharma, Inc. - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Digna Biotech, S.L. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - HEC Pharm Co., Ltd. - Histocell S.L. - iBio, Inc. - IMMD Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - NicOx S.A. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/76pwpp/pulmonary
PSTI: 1.65 (+0.03), GALT: 2.47 (+0.55), LLY: 80.44 (+0.56), BMY: 55.75 (+0.19), GLPG: 66.95 (-0.48), GILD: 81.61 (-0.17), IBIO: 0.55 (-0.01), TEVA: 50.35 (-0.01), FGEN: 21.66 (+0.07), CELGZ: 1.25 (+0.05)
Galectin Therapeutics Posts "2015-2016, Progress and Possibilities" to Corporate Website
GlobeNewswire - Thu Jan 07, 7:05AM CST
Galectin Therapeutics, Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that the year-in-review post "2015-2016, Progress and Possibilities" is now available on the company's website in the CEO Perspectives section here. Following is the text of the post.
GALT: 2.47 (+0.55)
Kidney Fibrosis - Pipeline Review 2015
M2 - Wed Jan 06, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/gj84k6/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Cellmid Limited - Evotec AG - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GNI Group Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - Lpath, Inc. - MorphoSys AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - SciFluor Life Sciences, LLC For more information visit http://www.researchandmarkets.com/research/gj...y_fibrosis
RPTP: 8.98 (+0.01), GALT: 2.47 (+0.55), ICPT: 168.44 (-1.57), RGLS: 3.40 (-0.04), ABBV: 63.94 (+0.66), LPTN: 3.49 (+0.15)
Severe Psoriasis - Pipeline Review 2015
M2 - Wed Jan 06, 4:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/wzbqp3/severe_psoriasis) has announced the addition of the "Severe Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Severe Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Severe Psoriasis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Severe Psoriasis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Almirall, S.A. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Celgene Corporation - Eli Lilly and Company - Forward Pharma A/S - Galectin Therapeutics, Inc. - Idera Pharmaceuticals, Inc. - Johnson & Johnson - Merck KGaA - Sandoz International GmbH - Sun Pharma Advanced Research Company Ltd. - Syntrix Biosystems, Inc. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/wz..._psoriasis
JNJ: 118.28 (+0.33), IDRA: 2.66 (-0.18), FWP: 21.00 (-0.60), AZN: 33.58 (-0.07), GALT: 2.47 (+0.55), LLY: 80.44 (+0.56), VRX.TO: 35.38 (+0.55), CELGZ: 1.25 (+0.05)
Galectin Therapeutics Announces Dismissals of Federal Securities Class Action and Shareholder Derivative Actions
GlobeNewswire - Tue Jan 05, 7:19AM CST
Galectin Therapeutics, Inc. (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced that the United States District Court for Northern Georgia has dismissed all claims against it and certain officers, directors and shareholder 10X Fund L.P. alleged in a Consolidated Securities Class Action originally filed in July 2014 and all claims against certain officers and directors alleged in a Consolidated Shareholder Derivative Action originally filed in August 2014.
GALT: 2.47 (+0.55)
Global Non-Alcoholic SteatoHepatitis (NASH) Analysis 2015 - Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunities
M2 - Fri Dec 11, 9:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/m95wfc/nonalcoholic) has announced the addition of the "Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunity in Various Geographies" report to their offering. Sales of Hepatitis C drugs crossed -$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative. Improved diagnosis rate and change in treatment guidelines along with defined clinical trials endpoint are the concerns for the emerging therapy. US FDA is expected to release guidelines for the clinical trial in CY16 and this should accelerate the development of the drugs targeting NASH. NASH is the progressive form of Non-Alcoholic Fatty Liver Disease - NAFLD. While NASH can reverse itself, in many cases, the resulting liver scarring causes a patient's liver to harden and failure to work properly. It is estimated that NASH affects 2 to 5% of the US population. Other developed countries such as Europe and Japan also have similar or higher incidence of NASH disease. Due to the varying physical and metabolism traits across various geographies, development of drugs for NASH is facing difficulty. In Japan, the prevalence of NASH is rising although the population is not typically overweight. Countries like India and China with bigger population and changes in lifestyles face a greater risk of NASH along with other lifestyle diseases like Diabetes and Cardiovascular related complexities. As per the US Association of Liver Disease, of those who develop NASH, -15-25% will progress to end stage liver disease (ESLD) and hepatocellular carcinoma (HCC) over 10-20 years. Today, 1/3rd of Liver transplants and HCC are caused by NASH and the total cost burden of this on US is over -$5 billion per year. Only new treatments in NASH could lead to a cut in this major cost burden along with improving quality of life. Since a new innovation in NASH has been enlightened, the interest in companies developing drugs for NASH has also gone up. In Jan. 2015, Gilead Sciences (GILD) acquired Phenex Pharma's Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH) and other Liver Diseases. Merck-NGM Biopharma and Boehringer Ingelheim - Pharmaxis also entered into an exclusive agreement for the pipeline products which are being developed for NASH with a potential deal value of -$450-600mn. This report will provide detailed analysis on NASH disease and Drugs in development in broader pharma market. This report list all the drugs in clinical trial and their design and the population recruited, also tells about the pathways representing possible targets for the treatment of NASH. Key Topics Covered: 1. Executive Summary 2. Overview of NASH 2.1 Possible targets for the treatment of NASH 2.2 Drugs in the pipeline 2.3 Key Milestones 2.4 Drivers of M&A/ Licensing deals in NASH 2.5 NASH disease market opportunity to 2025 3. Products in Development and Competitive Landscape 3.1 Key Drugs/Companies Developing Drugs Against NASH 3.1.1 Obeticholic Acid - Intercept Pharmaceuticals/ Dainippon Sumitomo 3.1.2 Elafibranor - Genfit 3.1.3 Multiple programs - Gilead 3.1.4 Emricasan - Conatus Pharmaceuticals 3.1.5 Aramchol - Galmed Pharmaceuticals 3.1.6 Cenicriviroc - Tobira Therapeutics 3.1.7 IMM-124E - Immuron 3.1.8 GR-MD-02 - Galectin Therapeutics 3.1.9 TD139 - Galecto Biotech 3.1.10 SHP626 - Shire 3.1.11 PXS4728A - Boehringer Ingelheim 3.2 Repurposed Drugs for NASH 3.2.1 Remogliflozin etabonate - Islet Sciences/BHV pharma 3.2.2 Lipaglyn (saroglitazar) - Cadila Healthcare 3.2.3 Victoza (liraglutide) - Novo Nordisk 4. NASH - Etiology, Pathogenesis, Diagnosis and Current Treatment 4.1 Cause, Symptoms, Pathogenesis, Diagnosis 4.2 Current treatment including Herbal Medicine 5. Regulatory Pathway 5.1 Challenges in trials using endpoints to define clinically meaningful benefits 5.2 Potential Clinical Trial Design for NASH and Endpoints 6. Annexure Companies Mentioned - Boehringer Ingelheim - Cadila Healthcare - Conatus Pharmaceuticals - Galectin Therapeutics - Galecto Biotech - Galmed Pharmaceuticals - Genfit - Gilead - Immuron, - Intercept Pharmaceuticals/ Dainippon Sumitomo - Islet Sciences/BHV pharma - Novo Nordisk - Shire - Tobira Therapeutics For more information visit http://www.researchandmarkets.com/research/m9...nalcoholic
NVO: 45.75 (-0.48), GLMD: 4.63 (+0.02), GILD: 81.61 (-0.17), MRK: 62.44 (+0.50), CNAT: 2.08 (-0.01), GALT: 2.47 (+0.55), ICPT: 168.44 (-1.57), TBRA: 39.00 (+0.09)
Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015
M2 - Fri Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/gd4hqf/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Aquinox Pharmaceuticals Inc. - Ardelyx, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Connexios Life Sciences Pvt. Ltd. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - DURECT Corporation - Dynavax Technologies Corporation - Enanta Pharmaceuticals, Inc. - Exicure, Inc. - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - iCo Therapeutics Inc. - Merck & Co., Inc. - Mochida Pharmaceutical Co., Ltd. - NGM Biopharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Novartis AG - Novo Nordisk A/S - Protalix BioTherapeutics, Inc. - Regulus Therapeutics Inc. - RuiYi Inc. - Shire Plc - Vascular Biogenics Ltd. - Verva Pharmaceuticals Limited - Viking Therapeutics, Inc. - Virobay Inc. - Zafgen Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/gd...nalcoholic
DVAX: 11.64 (-0.36), ZFGN: 3.27 (-0.07), AQXP: 13.15 (-0.28), GALT: 2.47 (+0.55), RGLS: 3.40 (-0.04), BMY: 55.75 (+0.19), DRRX: 1.72 (-0.03), ENTA: 26.71 (-0.04), NVO: 45.75 (-0.48), GILD: 81.61 (-0.17), SHPG: 204.08 (-2.48), MRK: 62.44 (+0.50), VBAY: (), VBLT: 4.78 (+0.15), VKTX: 1.28 (-0.02), NVS: 81.24 (+0.18)
Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
GlobeNewswire - Wed Aug 31, 7:00AM CDT
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the Company's president, chief executive officer and chief medical officer, will present at Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 3:50 p.m. Eastern time. The conference is being held at the New York Palace Hotel in New York City on September 11-13, 2016.
GALT: 2.47 (+0.55)
Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial
GlobeNewswire - Thu Aug 25, 7:00AM CDT
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announces interim results from an exploratory, open-label, Phase 2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis.
GALT: 2.47 (+0.55)
Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Tue Aug 09, 7:00AM CDT
Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September
GALT: 2.47 (+0.55)
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis
GlobeNewswire - Tue Aug 02, 7:45AM CDT
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the completion of patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis (the NASH-CX trial). The Company expects to report the topline results of this trial in December 2017, as previously planned.
GALT: 2.47 (+0.55)
Galectin Therapeutics (GALT) Jumps: Stock Rises 17.1%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:25AM CDT
Galectin Therapeutics, Inc. (GALT) moved big last session, as its shares jumped a little over 17% on the day.
GALT: 2.47 (+0.55)
Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension
GlobeNewswire - Thu Jun 02, 7:00AM CDT
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that GR-MD-02, its development-stage galectin-3 (gal-3) inhibitor, has shown a positive effect on vascular remodeling in an animal model of pulmonary arterial hypertension (PAH). The results were presented at the American Thoracic Society (ATS) 2016 International Conference by investigators from the Vascular Biology Center and the Department of Pharmacology and Toxicology at Augusta University (formerly known as Georgia Regents University) (see poster presentation).
GALT: 2.47 (+0.55)
Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis
GlobeNewswire - Mon May 16, 3:05PM CDT
A significant clearing of psoriasis in first four patients prompts the extension of treatment for an additional 12 weeks
GALT: 2.47 (+0.55)
Galectin Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Tue May 10, 7:00AM CDT
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three months ended March 31, 2016. These results are included in the Company's Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov.
GALT: 2.47 (+0.55)
Preclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at the American Thoracic Society 2016 International Conference
GlobeNewswire - Thu May 05, 7:01AM CDT
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, has received notification that its collaborative abstract with investigators at Augusta University "Galectin-3 Mediates Vascular Remodeling in Pulmonary Arterial Hypertension" has been accepted for presentation at the American Thoracic Society (ATS) 2016 International Conference, taking place May 13-18 in San Francisco.
GALT: 2.47 (+0.55)
Global Moderate Psoriasis Therapeutics Development Pipeline Review, H2 2015
M2 - Wed Feb 03, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/svzcsv/moderate) has announced the addition of the "Moderate Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Moderate Psoriasis Overview - Therapeutics Development - Pipeline Products for Moderate Psoriasis - Overview - Pipeline Products for Moderate Psoriasis - Comparative Analysis - Moderate Psoriasis - Therapeutics under Development by Companies - Moderate Psoriasis - Therapeutics under Investigation by Universities/Institutes - Moderate Psoriasis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Moderate Psoriasis - Products under Development by Companies - Moderate Psoriasis - Products under Investigation by Universities/Institutes - Moderate Psoriasis - Companies Involved in Therapeutics Development - AbGenomics International, Inc. - ADC Therapeutics Sarl - Almirall, S.A. - AstraZeneca Plc - Avexxin AS - Boehringer Ingelheim GmbH - Celgene Corporation - Convoy Therapeutics, Inc. - Crescendo Biologics Limited - Delenex Therapeutics AG - Eli Lilly and Company - Forward Pharma A/S - Galectin Therapeutics, Inc. - GlycoMar Limited - Idera Pharmaceuticals, Inc. - Johnson & Johnson - Merck KGaA - OPKO Health, Inc. - Sandoz International GmbH - Soligenix, Inc. - Sun Pharma Advanced Research Company Ltd. - Syntrix Biosystems, Inc. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/svzcsv/moderate
JNJ: 118.28 (+0.33), IDRA: 2.66 (-0.18), OPK: 10.56 (+0.06), FWP: 21.00 (-0.60), AZN: 33.58 (-0.07), GALT: 2.47 (+0.55), LLY: 80.44 (+0.56), VRX.TO: 35.38 (+0.55), CELGZ: 1.25 (+0.05)
Galectin Therapeutics to Present at Upcoming Conferences
GlobeNewswire - Thu Jan 28, 7:00AM CST
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today Peter G. Traber, MD, the Company's president, chief executive officer and chief medical officer will present at the 18 Annual BIO CEO & Investor Conference on February 8, 2016, at 10:30 a.m. and at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on February 11, 2016, at 12:00 p.m. Eastern Standard Time.
GALT: 2.47 (+0.55)
Myocardial Fibrosis Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/nbcrfp/myocardial) has announced the addition of the "Myocardial Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myocardial Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Myocardial Fibrosis Overview - Therapeutics Development - Pipeline Products for Myocardial Fibrosis - Overview - Pipeline Products for Myocardial Fibrosis - Comparative Analysis - Myocardial Fibrosis - Therapeutics under Development by Companies - Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes - Myocardial Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myocardial Fibrosis - Products under Development by Companies - Myocardial Fibrosis - Products under Investigation by Universities/Institutes - Myocardial Fibrosis - Companies Involved in Therapeutics Development - AstraZeneca Plc - BioLineRx, Ltd. - Digna Biotech, S.L. - Evotec AG - Galectin Therapeutics, Inc. - GTx, Inc. - MandalMed, Inc. - miRagen Therapeutics, Inc. - ProMetic Life Sciences Inc. - Virocan Therapeutics Private Limited For more information visit http://www.researchandmarkets.com/research/nbcrfp/myocardial
GTXI: 0.74 (-0.02), AZN: 33.58 (-0.07), GALT: 2.47 (+0.55)
Galectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors
GlobeNewswire - Fri Jan 08, 7:10AM CST
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the election of Marc Rubin, M.D. as Chairman of the Board of Directors. Dr. Rubin, who has been serving as lead independent Director, succeeds James C. Czirr, who helped found the Company in 2000 and has served as Executive Chairman for the past seven years. Mr. Czirr will continue to serve as a Director. Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and Board experience in the development and commercialization of pharmaceuticals.
CRIS: 2.33 (-0.04), TTNP: 6.05 (-0.02), GALT: 2.47 (+0.55)
Pulmonary Fibrosis - Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/76pwpp/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Pulmonary Fibrosis - Overview - Pipeline Products for Pulmonary Fibrosis - Comparative Analysis - Pulmonary Fibrosis - Therapeutics under Development by Companies - Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Pulmonary Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pulmonary Fibrosis - Products under Development by Companies - Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Angion Biomedica Corp. - aTyr Pharma, Inc. - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Digna Biotech, S.L. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - HEC Pharm Co., Ltd. - Histocell S.L. - iBio, Inc. - IMMD Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - NicOx S.A. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/76pwpp/pulmonary
PSTI: 1.65 (+0.03), GALT: 2.47 (+0.55), LLY: 80.44 (+0.56), BMY: 55.75 (+0.19), GLPG: 66.95 (-0.48), GILD: 81.61 (-0.17), IBIO: 0.55 (-0.01), TEVA: 50.35 (-0.01), FGEN: 21.66 (+0.07), CELGZ: 1.25 (+0.05)
Galectin Therapeutics Posts "2015-2016, Progress and Possibilities" to Corporate Website
GlobeNewswire - Thu Jan 07, 7:05AM CST
Galectin Therapeutics, Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that the year-in-review post "2015-2016, Progress and Possibilities" is now available on the company's website in the CEO Perspectives section here. Following is the text of the post.
GALT: 2.47 (+0.55)
Kidney Fibrosis - Pipeline Review 2015
M2 - Wed Jan 06, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/gj84k6/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Cellmid Limited - Evotec AG - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GNI Group Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - Lpath, Inc. - MorphoSys AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - SciFluor Life Sciences, LLC For more information visit http://www.researchandmarkets.com/research/gj...y_fibrosis
RPTP: 8.98 (+0.01), GALT: 2.47 (+0.55), ICPT: 168.44 (-1.57), RGLS: 3.40 (-0.04), ABBV: 63.94 (+0.66), LPTN: 3.49 (+0.15)
Severe Psoriasis - Pipeline Review 2015
M2 - Wed Jan 06, 4:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/wzbqp3/severe_psoriasis) has announced the addition of the "Severe Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Severe Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Severe Psoriasis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Severe Psoriasis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Almirall, S.A. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Celgene Corporation - Eli Lilly and Company - Forward Pharma A/S - Galectin Therapeutics, Inc. - Idera Pharmaceuticals, Inc. - Johnson & Johnson - Merck KGaA - Sandoz International GmbH - Sun Pharma Advanced Research Company Ltd. - Syntrix Biosystems, Inc. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/wz..._psoriasis
JNJ: 118.28 (+0.33), IDRA: 2.66 (-0.18), FWP: 21.00 (-0.60), AZN: 33.58 (-0.07), GALT: 2.47 (+0.55), LLY: 80.44 (+0.56), VRX.TO: 35.38 (+0.55), CELGZ: 1.25 (+0.05)
Galectin Therapeutics Announces Dismissals of Federal Securities Class Action and Shareholder Derivative Actions
GlobeNewswire - Tue Jan 05, 7:19AM CST
Galectin Therapeutics, Inc. (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced that the United States District Court for Northern Georgia has dismissed all claims against it and certain officers, directors and shareholder 10X Fund L.P. alleged in a Consolidated Securities Class Action originally filed in July 2014 and all claims against certain officers and directors alleged in a Consolidated Shareholder Derivative Action originally filed in August 2014.
GALT: 2.47 (+0.55)
Global Non-Alcoholic SteatoHepatitis (NASH) Analysis 2015 - Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunities
M2 - Fri Dec 11, 9:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/m95wfc/nonalcoholic) has announced the addition of the "Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in Development, Regulatory Guidelines and Market Opportunity in Various Geographies" report to their offering. Sales of Hepatitis C drugs crossed -$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative. Improved diagnosis rate and change in treatment guidelines along with defined clinical trials endpoint are the concerns for the emerging therapy. US FDA is expected to release guidelines for the clinical trial in CY16 and this should accelerate the development of the drugs targeting NASH. NASH is the progressive form of Non-Alcoholic Fatty Liver Disease - NAFLD. While NASH can reverse itself, in many cases, the resulting liver scarring causes a patient's liver to harden and failure to work properly. It is estimated that NASH affects 2 to 5% of the US population. Other developed countries such as Europe and Japan also have similar or higher incidence of NASH disease. Due to the varying physical and metabolism traits across various geographies, development of drugs for NASH is facing difficulty. In Japan, the prevalence of NASH is rising although the population is not typically overweight. Countries like India and China with bigger population and changes in lifestyles face a greater risk of NASH along with other lifestyle diseases like Diabetes and Cardiovascular related complexities. As per the US Association of Liver Disease, of those who develop NASH, -15-25% will progress to end stage liver disease (ESLD) and hepatocellular carcinoma (HCC) over 10-20 years. Today, 1/3rd of Liver transplants and HCC are caused by NASH and the total cost burden of this on US is over -$5 billion per year. Only new treatments in NASH could lead to a cut in this major cost burden along with improving quality of life. Since a new innovation in NASH has been enlightened, the interest in companies developing drugs for NASH has also gone up. In Jan. 2015, Gilead Sciences (GILD) acquired Phenex Pharma's Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH) and other Liver Diseases. Merck-NGM Biopharma and Boehringer Ingelheim - Pharmaxis also entered into an exclusive agreement for the pipeline products which are being developed for NASH with a potential deal value of -$450-600mn. This report will provide detailed analysis on NASH disease and Drugs in development in broader pharma market. This report list all the drugs in clinical trial and their design and the population recruited, also tells about the pathways representing possible targets for the treatment of NASH. Key Topics Covered: 1. Executive Summary 2. Overview of NASH 2.1 Possible targets for the treatment of NASH 2.2 Drugs in the pipeline 2.3 Key Milestones 2.4 Drivers of M&A/ Licensing deals in NASH 2.5 NASH disease market opportunity to 2025 3. Products in Development and Competitive Landscape 3.1 Key Drugs/Companies Developing Drugs Against NASH 3.1.1 Obeticholic Acid - Intercept Pharmaceuticals/ Dainippon Sumitomo 3.1.2 Elafibranor - Genfit 3.1.3 Multiple programs - Gilead 3.1.4 Emricasan - Conatus Pharmaceuticals 3.1.5 Aramchol - Galmed Pharmaceuticals 3.1.6 Cenicriviroc - Tobira Therapeutics 3.1.7 IMM-124E - Immuron 3.1.8 GR-MD-02 - Galectin Therapeutics 3.1.9 TD139 - Galecto Biotech 3.1.10 SHP626 - Shire 3.1.11 PXS4728A - Boehringer Ingelheim 3.2 Repurposed Drugs for NASH 3.2.1 Remogliflozin etabonate - Islet Sciences/BHV pharma 3.2.2 Lipaglyn (saroglitazar) - Cadila Healthcare 3.2.3 Victoza (liraglutide) - Novo Nordisk 4. NASH - Etiology, Pathogenesis, Diagnosis and Current Treatment 4.1 Cause, Symptoms, Pathogenesis, Diagnosis 4.2 Current treatment including Herbal Medicine 5. Regulatory Pathway 5.1 Challenges in trials using endpoints to define clinically meaningful benefits 5.2 Potential Clinical Trial Design for NASH and Endpoints 6. Annexure Companies Mentioned - Boehringer Ingelheim - Cadila Healthcare - Conatus Pharmaceuticals - Galectin Therapeutics - Galecto Biotech - Galmed Pharmaceuticals - Genfit - Gilead - Immuron, - Intercept Pharmaceuticals/ Dainippon Sumitomo - Islet Sciences/BHV pharma - Novo Nordisk - Shire - Tobira Therapeutics For more information visit http://www.researchandmarkets.com/research/m9...nalcoholic
NVO: 45.75 (-0.48), GLMD: 4.63 (+0.02), GILD: 81.61 (-0.17), MRK: 62.44 (+0.50), CNAT: 2.08 (-0.01), GALT: 2.47 (+0.55), ICPT: 168.44 (-1.57), TBRA: 39.00 (+0.09)
Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015
M2 - Fri Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/gd4hqf/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Aquinox Pharmaceuticals Inc. - Ardelyx, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Connexios Life Sciences Pvt. Ltd. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - DURECT Corporation - Dynavax Technologies Corporation - Enanta Pharmaceuticals, Inc. - Exicure, Inc. - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - iCo Therapeutics Inc. - Merck & Co., Inc. - Mochida Pharmaceutical Co., Ltd. - NGM Biopharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Novartis AG - Novo Nordisk A/S - Protalix BioTherapeutics, Inc. - Regulus Therapeutics Inc. - RuiYi Inc. - Shire Plc - Vascular Biogenics Ltd. - Verva Pharmaceuticals Limited - Viking Therapeutics, Inc. - Virobay Inc. - Zafgen Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/gd...nalcoholic
DVAX: 11.64 (-0.36), ZFGN: 3.27 (-0.07), AQXP: 13.15 (-0.28), GALT: 2.47 (+0.55), RGLS: 3.40 (-0.04), BMY: 55.75 (+0.19), DRRX: 1.72 (-0.03), ENTA: 26.71 (-0.04), NVO: 45.75 (-0.48), GILD: 81.61 (-0.17), SHPG: 204.08 (-2.48), MRK: 62.44 (+0.50), VBAY: (), VBLT: 4.78 (+0.15), VKTX: 1.28 (-0.02), NVS: 81.24 (+0.18)
